首页> 外文期刊>Materia Medica Polona >Comparative pharmacokinetics and bioavailability of flavonoid glycosides of Ginkgo biloba after a single oral administration of three formulations to healthy volunteers
【24h】

Comparative pharmacokinetics and bioavailability of flavonoid glycosides of Ginkgo biloba after a single oral administration of three formulations to healthy volunteers

机译:对健康志愿者单次口服三种制剂后,银杏叶黄酮苷的比较药代动力学和生物利用度

获取原文
获取原文并翻译 | 示例
           

摘要

Eighteen healthy volunteers received three different formulations of Ginkgo biloba: capsules (A) and drops (B) (delivered by Agon Pharma), and tablets (C) (Tebonin - Dr. W. Schwabe) in equal an quantity, orally as a single dose, at an interval of at least five days. The pharmacokinetic parameters of the most important flavonoid glycosides: quercetin, kaempferol and isorhanmetin were established. The bioavai-lability was estimated using capsules as a standard formulation. Only the time to reach the peak concentration (tmax) of quercetin, kaempforol and isorhanmetin administered in the form of capsules, was significantly prolonged as compared with drops and tablets. Area under the curve (AUC) was the largest for formulation B for all the evaluated flavonoid glycosides, however the differences were not statistically significant. It is concluded that the three formulations of Ginkgo biloba extract are bioequivalent.
机译:18名健康志愿者接受了三种不同剂量的银杏制剂:胶囊(A)和滴剂(B)(由Agon Pharma运送)和片剂(C)(Tebonin-W. Schwabe博士)等量口服,一次服用至少间隔五天。建立了最重要的类黄酮糖苷的药代动力学参数:槲皮素,山奈酚和异山han素。使用胶囊作为标准制剂评估生物利用度。与滴剂和片剂相比,只有达到槲皮素,山奈酚和异山met素以胶囊形式达到峰值浓度(tmax)的时间才显着延长。对于所有评估的类黄酮糖苷而言,制剂B的曲线下面积(AUC)最大,但是差异无统计学意义。结论是银杏叶提取物的三种配方具有生物等效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号